Research Article

You have full text access to this OnlineOpen article

Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis

  1. Gary S. Hoffman1,†,*,
  2. Peter A. Merkel2,†,
  3. Richard D. Brasington3,
  4. Deborah J. Lenschow3,
  5. Patrick Liang1

Article first published online: 6 JUL 2004

DOI: 10.1002/art.20300

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 50, Issue 7, pages 2296–2304, July 2004

Additional Information

How to Cite

Hoffman, G. S., Merkel, P. A., Brasington, R. D., Lenschow, D. J. and Liang, P. (2004), Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis & Rheumatism, 50: 2296–2304. doi: 10.1002/art.20300

Author Information

  1. 1

    Cleveland Clinic Foundation, Cleveland, Ohio

  2. 2

    Boston University School of Medicine, Boston, Massachusetts

  3. 3

    Washington University School of Medicine, St. Louis, Missouri

  1. †

    Drs. Hoffman and Merkel have also been investigators of studies evaluating anti–tumor necrosis factor (anti-TNF) therapies in Wegener's granulomatosis and giant cell arteritis, which were partially funded by Centocor, Immunex, and Amgen. Dr. Brasington has also been an investigator of a study evaluating the role of anti-TNF therapy in rheumatoid arthritis, which was funded by Amgen, and has received speaker's fees from Immunex, Amgen, and Centocor.

*Harold C. Schott Chair for Rheumatic and Immunologic Diseases and Director, Center for Vasculitis Care and Research, A50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Publication History

  1. Issue published online: 6 JUL 2004
  2. Article first published online: 6 JUL 2004
  3. Manuscript Accepted: 1 MAR 2004
  4. Manuscript Received: 13 NOV 2003

Funded by

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases. Grant Number: K24 AR-2224-01A1

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (240K)

REFERENCES

  • 1
    Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med 1994; 120: 919–29.
  • 2
    Seko Y. Takayasu arteritis. In: HoffmanGS, WeyandC, editors. Inflammatory diseases of the blood vessels. New York: Marcel Dekker; 2002. p. 443–53.
  • 3
    Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001; 44: 2933–5.
    Direct Link:
  • 4
    Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G. Experience with infliximab (anti-TNF monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003; 62: 1116.
  • 5
    Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129–34.
    Direct Link:
  • 6
    Tso E, Flamm SD, White RD, Schvartzman PR, Mascha E, Hoffman GS. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002; 46: 1634–42.
    Direct Link:
  • 7
    Reny J, Paul JF, Lefebvre C, Champion K, Emmerich J, Bletry O, et al. Association of Takayasu's arteritis and Crohn's disease: results of a study on 44 Takayasu's patients and a review of the literature. Ann Med Interne (Paris) 2003; 154: 85–90.
  • 8
    Maksimowicz-McKinnon K, Hoffman GS. Crohn's disease plus Takayasu's arteritis: more than coincidence? Ann Med Interne (Paris) 2003; 154: 75–6.
View Full Article (HTML) Get PDF (240K)